ATG-008 Combined With Toripalimab in Advanced Solid Tumors
This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.
Advanced Solid Tumor
DRUG: ATG-008|DRUG: Toripalimab
MTD, Maximum Tolerated Dose, Within 21 days after dosing|RP2D, Recommended phase 2 dose, Within 21 days after dosing|ORR, Overall Response Rate, Through study completion (approximately 2 years)
Cmax, Peak Plasma Concentration (Cmax), Day 1 - Day 15|AUC, Area under the plasma concentration versus time curve (AUC), Day 1 - Day 15|DOR, Duration from the first observation of at least PR to time of disease progression, or deaths due to disease progression, whichever occurs first., 12 months|DCR, Disease Control Rate (DCR=CBR+Stable Disease\[SD; for a minimum of 12 weeks\]), 12 months|PFS, Duration from start of study treatment to PD or death (regardless of cause), whichever comes first, 12 months|OS, The estimates of Kaplan-Meier, 12 months
This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.